Clinical Trial Update: TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL ) [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial evaluating infliximab (Remicade) for active lupus nephritis (WHO Class V) has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis
• Systemic Lupus Erythematosus

Drugs mentioned

• Remicade (infliximab)

Snippet

Sponsor: Medical University of Vienna | Conditions: Lupus Erythematosus, Systemic, Lupus Nephritis | Phase 2, Phase 3 | Status: TERMINATED